FDA Appoval....and a new standard in a significant global market4 Nov 2020 17:57
Now that the FDA has granted market clearance, IB and AI Metrics will begin to actively market and sell LSN in the USA. CE mark for European distribution and commercialisation is expected later this quarter.
''LSN's proprietary algorithms process CT images of a patient's liver to assess the nodules along the liver surface. This low cost, low-risk, non-invasive procedure provides physicians with new information that may aid in the staging of CLD and has the potential to become the standard of care for a significant global market....''
Selling starts this Q2020! and last time they said they are talking to potential buyers in advance - so huge re-rate tomorrow the way it closed on over 50% of total volume, and 30% is held by management and rest by others.
If can add/ buy under 15/16p will consider self lucky - we may well see huge rally on this one now - my guess and agree with other informed posters here, and elsewhere, we may see 50/6op by Q1. So lo of room to grow - short term good, long term good. These are hard to find.
See below:
Trevor Brown 43,419,766 29.75%
Kathleen Schmainda* 9,108,400 6.24%
West Coast Capital Investments 7,559,934 5.18%
Total shares = 145M, low float and not much for every body else. Not now after 80M volume day..
So hold tight to what you been able to grab OR buy early. We may end selling this over 100p+ in 2021.
Tomorrow we may well be over 25p or there about, as people add to core positions, and buy in.